Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
25
-
Total 13F principal, excl. options
-
261,971,087
-
Principal change
-
+4,093,500
-
Total reported value, excl. options
-
$306,514,595
-
Value change
-
+$5,146,358
-
Number of buys
-
11
-
Number of sells
-
-11
-
Price
-
$1.17
Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2021
30 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q2 2021.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $261,971,087 of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($104,329,000 of principal), FRANKLIN RESOURCES INC ($48,000,000 of principal), LAZARD ASSET MANAGEMENT LLC ($20,000,000 of principal), ZAZOVE ASSOCIATES LLC ($15,910,000 of principal), CAPSTONE INVESTMENT ADVISORS, LLC ($12,500,000 of principal), PUTNAM INVESTMENTS LLC ($8,919,000 of principal), Nuveen Asset Management, LLC ($8,675,000 of principal), MORGAN STANLEY ($7,152,000 of principal), ROYAL BANK OF CANADA ($4,932,000 of principal), and DeepCurrents Investment Group LLC ($4,918,000 of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.